Search

Displaying results 1931 - 1940 of 4190 in total
  1. Drug

    Delgocitinib

    go.drugbank.com/drugs/DB16133
    ApprovedInvestigational

    Delgocitinib is a pan-Janus kinase (JAK) inhibitor. After the first global approval in Japan, delgocitinib was also approved by the European Commission on September 23, 2024. It works to reduce the inflammatory response in inflammatory s...

  2. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    [L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349]

  3. Drug

    Ulobetasol

    go.drugbank.com/drugs/DB00596
    Approved

    Ulobetasol is a highly potent corticosteroid. It is structurally related to clobetasol. Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses. Ulobetasol was...

  4. Drug

    Delamanid

    go.drugbank.com/drugs/DB11637
    ApprovedInvestigational

    Delamanid is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall . It is used in the treatment of multidrug-resistant and extensively dru...

  5. Drug

    Nylidrin

    go.drugbank.com/drugs/DB06152
    ApprovedWithdrawn

    Nylidrin, also known as buphenine belongs to the category of drugs called vasodilators, which relax blood vessels and increase blood flow. Nylidrin is a peripheral vasodilator. Some studies show the evidence of improving cognitive impair...

  6. Drug

    Tridihexethyl

    go.drugbank.com/drugs/DB00505
    ApprovedWithdrawn

    Tridihexethyl is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.

  7. Drug

    LLL-3348

    go.drugbank.com/drugs/DB05771
    Experimental

    The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.

  8. Drug

    PEV3A

    go.drugbank.com/drugs/DB05144
    Investigational

    PEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. It is a two-component vaccine that contains the virosome formulated peptide mimetics PEV301 and PEV302.

  9. Drug

    Mersalyl

    go.drugbank.com/drugs/DB09338
    Experimental

    Interestingly, it has been found to have antiviral properties in mice [L1584]. … It is an outdated drug, and its approval has been discontinued by the FDA. Mersalyl acid is currently replaced by less toxic non-mercury containing diuretics [L1575, L1577].

  10. Drug

    Indomethacin

    go.drugbank.com/drugs/DB00328
    ApprovedInvestigational

    [L10553] Ophthalmic indometacin has been studied and used in the symptomatic treatment of postoperative ocular inflammation and pain and/or complications after cataract surgery. … [A177871] Since then, indometacin has been extensively studied in clinical trials as one of the most potent NSAIDs in blocking prostaglandin synthesis and was among the first NSAIDs to be used in the symptomatic